BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
49 results:

  • 1. Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human Colorectal cancer Cells: Implications in Therapy.
    Sinha BK; Bortner CD; Jarmusch AK; Tokar EJ; Murphy C; Wu X; Winter H; Cannon RE
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371096
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Acquisition of Genetic Aberrations During the Progression of High-Grade Intraepithelial Lesions/Micro-Invasive Squamous cancers to Widely Invasive Cervical Squamous Cell cancer.
    Kashofer K; Reich O; Regauer S
    Arch Pathol Lab Med; 2023 Dec; 147(12):1438-1445. PubMed ID: 36800542
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases.
    Han L; Guo X; Du R; Guo K; Qi P; Bian H
    J Ovarian Res; 2022 Jun; 15(1):75. PubMed ID: 35739532
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.
    Liu M; Wang D; Luo Y; Hu L; Bi Y; Ji J; Huang H; Wang G; Zhu L; Ma J; Kim E; Luo CK; Abbruzzese JL; Li X; Yang VW; Li Z; Lu W
    Cell Death Dis; 2021 Feb; 12(2):189. PubMed ID: 33594044
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
    Taylan E; Zayou F; Murali R; Karlan BY; Pandol SJ; Edderkaoui M; Orsulic S
    Gynecol Oncol; 2020 Oct; 159(1):277-284. PubMed ID: 32698955
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. ovarian mucinous tumors with mural nodules: immunohistochemical and molecular analysis of 3 cases.
    Shao Y; Liu Q; Shi H; Lu B
    Diagn Pathol; 2020 Apr; 15(1):35. PubMed ID: 32290854
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
    Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B
    J Clin Oncol; 2020 Jul; 38(19):2140-2150. PubMed ID: 32182156
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
    Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The levels of mutant k-ras and mutant n-ras are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel
    Shih TC; Liu R; Fung G; Bhardwaj G; Ghosh PM; Lam KS
    Mol Cancer Ther; 2017 Jul; 16(7):1212-1223. PubMed ID: 28396365
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Familial pancreatic cancer: Concept, management and issues.
    Matsubayashi H; Takaori K; Morizane C; Maguchi H; Mizuma M; Takahashi H; Wada K; Hosoi H; Yachida S; Suzuki M; Usui R; Furukawa T; Furuse J; Sato T; Ueno M; Kiyozumi Y; Hijioka S; Mizuno N; Terashima T; Mizumoto M; Kodama Y; Torishima M; Kawaguchi T; Ashida R; Kitano M; Hanada K; Furukawa M; Kawabe K; Majima Y; Shimosegawa T
    World J Gastroenterol; 2017 Feb; 23(6):935-948. PubMed ID: 28246467
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
    Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
    Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Disruption of endothelial adherens junction by invasive breast cancer cells is mediated by reactive oxygen species and is attenuated by AHCC.
    Haidari M; Zhang W; Wakame K
    Life Sci; 2013 Dec; 93(25-26):994-1003. PubMed ID: 24211779
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.
    Kulkarni AA; Roy B; Rao PS; Wyant GA; Mahmoud A; Ramachandran M; Sengupta P; Goldman A; Kotamraju VR; Basu S; Mashelkar RA; Ruoslahti E; Dinulescu DM; Sengupta S
    Cancer Res; 2013 Dec; 73(23):6987-97. PubMed ID: 24121488
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.
    Colombo PE; Fabbro M; Theillet C; Bibeau F; Rouanet P; Ray-Coquard I
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):207-16. PubMed ID: 24071502
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of k-ras mutations: a morphologic and molecular correlation study.
    Xiong J; He M; Jackson C; Ou JJ; Sung CJ; Breese V; Steinhoff MM; Quddus MR; Tejada-Berges T; Lawrence WD
    Int J Gynecol Cancer; 2013 Sep; 23(7):1231-6. PubMed ID: 23851676
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunobiology of human mucin 1 in a preclinical ovarian tumor model.
    Budiu RA; Elishaev E; Brozick J; Lee M; Edwards RP; Kalinski P; Vlad AM
    Oncogene; 2013 Aug; 32(32):3664-75. PubMed ID: 22964632
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens].
    Honda K; Hata Y; Ihara E; Tomita Y; Miyata S; Sumida Y; Ihara Y; Misawa T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1533-6. PubMed ID: 21918357
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
    Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.